Medical and psychiatric comorbidities: Complicating treatment expectations

Treatment-Refractory Schizophrenia: A Clinical Conundrum

Volumn , Issue , 2014, Pages 45-64

  Miller, Brian J ^a   Buckley, Peter F ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84956773193     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-45257-4_4     Document Type: Chapter

References (91)

1. Ahmed M, Hussain I, O’Brien SM, Dineen B, Griffin D, McDonald C (2008) Prevalence and associations of the metabolic syndrome among patients prescribed clozapine. Ir J Med Sci 177 (3):205-210
2. Annamraju S, Sheitman B, Saik S, Stephenson A (2007) Early recognition of clozapine-induced myocarditis. J Clin Psychopharmacol 27:479-483
3. Ball MP, Warren KR, Feldman S, McMahon RP, Kelly DL, Buchanan RW (2011) Placebocontrolled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizophr Relat Psychoses 5(1):17-25
4. Baptista T, ElFakih Y, Uzcátegui E, Sandia I, Tálamo E, Araujo de Baptista E, Beaulieu S (2008) Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 22 (6):477-495
5. Beumer W, Drexhage RC, De Wit H, Versnel MA, Drexhage HA, Cohen D (2012) Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology 37(12):1901-1911
6. Borovicka MC, Fuller MA, Konicki PE, White JC, Steele VM, Jaskiw GE (2002) Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. J Clin Psychiatry 63(4):345-348
7. Brunette MF, Drake RE, Xie H, McHugo GJ, Green AI (2006) Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull 32(4):637-643
8. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W (2010) Schizophrenia patient outcomes research team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36(1):71-93
9. Buckley P, Miller B, Lehrer D, Castle DJ (2009) Psychiatric comorbidities and schizophrenia. Schizophr Bull 35(2):383-402
10. Carrizo E, Fernández V, Quintero J, Connell L, Rodríguez Z, Mosquera M (2008) Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophr Res 103(1-3):83-93
11. Carrizo E, Fernández V, Connell L, Sandia I, Prieto D, Mogollón J, Valbuena D, Fernández I, de Baptista EA, Baptista T (2009) Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebocontrolled study. Schizophr Res 113(1):19-26
12. Cawthon RM, Smith KR, O’Brien E, Sivatchenko A, Kerber RA (2003) Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 361:393-395
13. Chen DC, Qi LY, Xiu MH, Cao LY, Wang F, Chen S, Wu GY, Kosten TA, Kosten TR, Zhang XY (2008) Elevated serum levels of tumor necrosis factor-α in clozapine-associated obesity in chronic schizophrenia. Schizophr Res 106(2-3):367-368
14. Cohen D, Bogers JP, van Dijk D, Bakker B, Schulte PF (2012) Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry 73(10):1307-1312
15. Coodin S, Ballegeer T (2000) Clozapine therapy and pulmonary embolism. Can J Psychiatry 45:395
16. Das C, Mendez G, Jagasia S, Labbate LA (2012) Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. Ann Clin Psychiatry 24(3):225-239
17. De Hert M, Correll CU, Cohen D (2010) Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res 117 (1):68-74
18. Devaraj S, Valleggi S, Siegel D, Jialal I (2010) Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome. Curr Atheroscler Rep 12:110-118
19. Dieset I, Hope S, Ueland T, Bjella T, Agartz I, Melle I, Aukrust P, Røssberg JI, Andreassen OA (2012) Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein. Schizophr Res 140(1-3):169-174
20. Drake RE, Xie H, McHugo GJ et al (2000) The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 26(2):441-449
21. Ehret M, Goethe J, Lanosa M, Coleman CI (2010) The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. J Clin Psychiatry 71(10):1286-1292
22. Fan X, Liu EY, Freudenreich O, Park JH, Liu D, Wang J, Yi Z, Goff D, Henderson DC (2010) Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. Schizophr Res 118:211-217
23. Fawzi MH, Fawzi MM, Fawzi MM, Said NS (2011) C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res 190(1):91-97
24. Fernandez-Egea E, Bernardo M, Heaphy CM, Griffith JK, Parellada E, Esmatjes E, Conget I, Nguyen L, George V, Stöppler H, Kirkpatrick B (2009) Telomere length and pulse pressure in newly diagnosed, antipsychotic-naive patients with nonaffective psychosis. Schizophr Bull 35 (2):437-442
25. Fontain KR, Heo M, Harrigan EP, Shear CL, Lakshminarayanan M, Casey DE, Allison DB (2001) Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 101:277-288
26. Galassi A, Reynolds K, He J (2006) Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 119:812-819
27. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F (2005) American heart association; national heart, lung, and blood institute diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation 112:2735-2752
28. Haas SJ, Hill R, Krum H, Liew D, Tonkin A, Demos L, Stephan K, McNeil J (2007) Clozapineassociated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 30(1):47-57
29. Hägg S, Lindblom Y, Mjörndal T, Adolfsson R (2006) High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 21(2):93-98
30. Hahn MK, Remington G, Bois D, Cohn T (2010) Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects. J Clin Psychopharmacol 30 (6):706-710
31. Hamner MB (1996) Clozapine treatment for a veteran with comorbid psychosis and PTSD. Am J Psychiatry 153(6):841
32. Harris EC, Barraclough B (1998) Excess mortality of mental disorder. Br J Psychiatry 173:11-53
33. Henderson DC, Daley TB, Kunkel L, Rodrigues-Scott M, Koul P, Hayden D (2004) Clozapine and hypertension: a chart review of 82 patients. J Clin Psychiatry 65(5):686-689
34. Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, Freudenreich O, Evins AE, Cather C, GoffDC (2005) Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 66(9):1116-1121
35. Henderson DC, Fan X, Copeland PM, Borba CP, Daley TB, Nguyen DD, Zhang H, Hayden D, Freudenreich O, Cather C, Evins AE, Goff DC (2007) A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand 115(2):101-105
36. Hennen J, Baldessarini RJ (2005) Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res 73(2-3):139-145
37. Hoang U, Stewart R, Goldacre MJ (2011) Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006. BMJ 343:d5422
38. Kao HT, Cawthon RM, Delisi LE, Bertisch HC, Ji F, Gordon D, Li P, Benedict MM, Greenberg WM, Porton B (2008) Rapid telomere erosion in schizophrenia. Mol Psychiatry 13(2):118-119
39. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R (2010) C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375:132-140
40. Kelly DL, McMahon RP, Liu F, Love RC, Wehring HJ, Shim JC, Warren KR, Conley RR (2010) Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry 71(3):304-311
41. Kelly TM, Daley DC, Douaihy AB (2012) Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behav 37(1):11-24
42. Kluge M, Schuld A, Schacht A, Himmerich H, Dalal MA, Wehmeier PM, Hinze-Selch D, Kraus T, Dittmann RW, Pollmächer T (2009) Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology 34 (1):118-128
43. Ko YH, Joe SH, Jung IK, Kim SH (2005) Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 28 (4):169-175
44. Leo CA (1979) Therapeutic effects of clozapine. A 4-year follow-up of a controlled clinical trial. Acta Psychiatr Scand 59:471-480
45. Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, Ji Z, Koch G, Hamer RM (2003) Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 28 (5):995-1003
46. Löffler S, Löffler-Ensgraber M, Fehsel K, Klimke A (2010a) Clozapine therapy raises serum concentrations of high sensitive C-reactive protein in schizophrenic patients. Int Clin Psychopharmacol 25(2):101-106
47. Löffler S, Klimke A, Kronenwett R, Kobbe G, Haas R, Fehsel K (2010b) Clozapine mobilizes CD34+ hematopoietic stem and progenitor cells and increases plasma concentration of interleukin 6 in patients with schizophrenia. J Clin Psychopharmacol 30(5):591-595
48. Lu ML, Lane HY, Lin SK, Chen KP, Chang WH (2004) Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 65(6):766-771
49. Machielsen MW, de Haan L (2009) Differences in efficacy on substance abuse between risperidone and clozapine supports the importance of differential modulation of dopaminergic neurotransmission. Psychopharmacol Bull 42(4):40-52
50. Machielsen M, Beduin AS, Dekker N, Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I Genetic Risk and Outcome of Psychosis (GROUP) investigators (2012) Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. J Psychopharmacol 26 (1):189-95
51. Mangalore R, Knapp M (2007) Cost of schizophrenia in England. J Ment Health Policy Econ 10:23-41
52. McEvoy JP (2007) The costs of schizophrenia. J Clin Psychiatry 68(suppl 14):4-7
53. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S (2003) International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60(1):82-91
54. Miller BJ (2011) Hospitalization for schizophrenia and bipolar disorder: a critical window to recognize and modify mortality risk. Invited editorial. Br Med J 343:d5652
55. Miller BJ, Paschall CB, Svendsen DP (2006) Mortality and medical comorbidity among patients with serious mental illness. Psychiatr Serv 57(10):1482-1487
56. Miller B, Pihlajamaa J, Haukka J, Cannon M, Henriksson M, Hannele H, Huttunen M, Tanskanen A, Lönnqvist J, Suvisaari J, Kirkpatrick B (2010a) Paternal age and mortality in nonaffective psychosis. Schizophr Res 121(1-3):218-226
57. Miller BJ, Alaräisänen A, Miettunen J, Järvelin MR, Koponen H, Räsänen P, Isohanni M, Kirkpatrick B (2010b) Advanced paternal age, mortality, and suicide in the general population. J Nervous Mental Dis 198(6):404-411
58. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70 (7):663-671
59. Miller B, Mellor A, Buckley P (2013) Total and differential white blood cell counts, highsensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses. Brain Behav Immun 31:82-89
60. Miller BJ, Culpepper N, Rapaport MH (2013) C-reactive protein in schizophrenia: a review and meta-analysis. Clin Schizophr Relat Psychoses 21:1-22
61. Moller DE (2000) Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 11(6):212-217
62. Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Robinson DG, Schooler NR, Shon SP, Stroup TS, Miller AL (2007) The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 68(11):1751-1762
63. Mukherjee S, Schnur DB, Reddy R (1989) Family history of type 2 diabetes in schizophrenic patients. Lancet 1:495
64. Murthy P, Chand P (2012) Treatment of dual diagnosis disorders. Curr Opin Psychiatry 25(3):194-200
65. Narula PK, Rehan HS, Unni KE, Gupta N (2010) Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebocontrolled trial. Schizophr Res 118(1-3):218-223
66. O’Keefe CD, Noordsy DL, Liss TB, Weiss H (2003) Reversal of antipsychotic-associated weight gain. J Clin Psychiatry 64(8):907-912
67. Obana N, Takagi S, Kinouchi Y et al (2003) Telomere shortening of peripheral blood mononuclear cells in coronary disease patients with metabolic disorders. Intern Med 42:150-153
68. Palmer BA, Pankratz VS, Bostwick JM (2005) The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 62(3):247-253
69. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH (2000) QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355:1048-1052
70. Reznik I, Yavin I, Stryjer R, Spivak B, Gonen N, Strous R, Mester R, Weizman A, Kotler M (2004) Clozapine in the treatment of obsessive-compulsive symptoms in schizophrenia patients: a case series study. Pharmacopsychiatry 37(2):52-56
71. Røge R, Møller BK, Andersen CR, Correll CU, Nielsen J (2012) Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr Res 140(1-3):204-213
72. Saha S, Chant D, McGrath J (2007) A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 64:1123-1131
73. Sampson MJ, Winterbone MS, Hughes JC, Dozio N, Hughes DA (2006) Monocyte telomere shortening and oxidative DNA damage in type 2 diabetes. Diabetes Care 29:283-289
74. Schirmbeck F, Zink M (2012) Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Curr Neuropharmacol 10(1):88-95
75. Shcherbakova I, Neshkova E, Dotsenko V, Platonova T, Shcherbakova E, Yarovaya G (1999) The possible role of plasma kallikrein-kinin system and leukocyte elastase in pathogenesis of schizophrenia. Immunopharmacology 43(2-3):273-279
76. Smith DJ, Langan J, McLean G, Guthrie B, Mercer SW (2013) Schizophrenia is associated wiThexcess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: cross-sectional study. BMJ Open 3(4):e002808
77. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH (2007) Impaired glucose tolerance in first-episode drug-naı¨ve patients with schizophrenia. Diabet Med 24(5):481-485
78. Spivak B, Shabash E, Sheitman B, Weizman A, Mester R (2003) The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. J Clin Psychiatry 64(7):755-760
79. Strassnig M, Ganguli R (2007) Weight loss interventions for patients with schizophrenia. Clin Schizophr Relat Psychoses 1(1):43-53
80. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374(9690):620-627
81. Tovey E, Rampes H, Livingstone C (2005) Clozapine-induced type-2 diabetes mellitus: possible mechanisms and implications for clinical practice. J Psychopharmacol 19:207-210
82. Waddington JL, Youssef HA, Kinsella A (1998) Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 173:325-329
83. Walker AM, Lanza LL, Arellano F, Rothman KJ (1997) Mortality in current and former users of clozapine. Epidemiology 8(6):671-677
84. Wheatley M, Plant J, Reader H, Brown G, Cahill C (2004) Clozapine treatment of adolescents with posttraumatic stress disorder and psychotic symptoms. J Clin Psychopharmacol 24(2):167-173
85. WHO (2009) Global health risks: mortality and burden of disease attributable to selected major risks. ISBN: 978 92 4 1563871. http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf
86. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, Tang JS (2006) Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl) 186(4):572-578
87. Wu MK, Wang CK, Bai YM, Huang CY, Lee SD (2007) Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatr Serv 58(4):544-550
88. Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, He YQ, Liu YJ, Chen JD, Li LH (2008) Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 299(2):185-193
89. Yu WY, Chang HW, Lin CH, Cho CL (2008) Short telomeres in patients with chronic schizophrenia who show a poor response to treatment. J Psychiatry Neurosci 33(3):244-247
90. Zai G, Müller DJ, Volavka J, Czobor P, Lieberman JA, Meltzer HY, Kennedy JL (2006) Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication. Psychopharmacology (Berl) 188 (2):171-182
91. Zhang X, Hui L, Liu Y, Wang Z-Q, You Y, Miao L, Sun S-L, Guan S-L, Xiang Y, Kosten TR, Zhang ZY (2013) The type 2 diabetes mellitus susceptibility gene IGF2BP2 is associated with schizophrenia in a Han Chinese population. J Clin Psychiatry 74(4):e287-e292